PolyActiva and RareSight Inc. have announced a strategic collaboration to develop first-in-class therapies for rare pediatric retinal diseases that currently have no approved drug treatments.
The research collaboration agreement, leveraging PolyActiva’s proprietary PREZIA™ platform, will offer first-of-its-kind, new chemical entity (NCE)-eligible pro-drug candidates to people affected by blinding eye conditions.
PolyActiva’s Chief Scientific Officer, Michael Brubaker, Ph.D., will present a corporate overview of the company’s proprietary PREZIA™ drug delivery platform at Eyecelerator @ the American Academy of Ophthalmology (AAO) 2025 Annual Meeting on Thursday, October 16, 2025, in Orlando, Florida.
PolyActiva has announced the first U.S. patient has been enrolled in our Phase 2b clinical trial evaluating PA5108, an investigational new chemical entity, intracameral ocular micro implant, for the reduction of intraocular pressure in patients with primary open-angle glaucoma and ocular hypertension.
PolyActiva has expanded their Executive Team, appointing Wes Brazell as Chief Financial Officer, and Michael Brubaker, PhD, as Chief Scientific Officer. Their appointments come at an important time for the company, following the recent appointment of Jerry St. Peter as Chief Executive Officer, and Vanessa Waddell continuing in her key leadership role as Chief Strategy Officer.
With this bolstered executive team, PolyActiva is poised to scale globally and advance the lead product candidate, PA5108, into late-stage clinical development.
PolyActiva has announced the next important milestone of our transformational growth – the appointment of seasoned biopharmaceutical executive, Jerry St. Peter, as CEO and Board Director of PolyActiva, following the successful close of our $40M AUD ($25M USD) Series C financing.
PolyActiva has recently secured $40 million (AUD) in Series C funding, led by the Australian National Reconstruction Fund (NRFC), and Australia’s leading biotech investor, Brandon Capital.
The funds will support the continued clinical advancement of PolyActiva’s lead ocular implant, PA5108, as it progresses to Series 2b clinical trials in the US. In addition to advancing PA5108, PolyActiva plans to use these funds to broaden their pipeline and explore new therapeutic opportunities enabled by its proprietary PREZIA™ platform technology.
PolyActiva has showcased their Phase 2 clinical data for their lead candidate PA5108 Ocular Implant in glaucoma patients.
Patients received continuous therapy for intraocular pressure (IOP) for over 48 weeks, receiving their first and second implants at week 0 and 21 respectively. Clinically meaningful IOP reductions of 26-35% were observed over the 48-week treatment period, and 94% of patients did not require additional drop therapy.
PolyActiva has recently been awarded a $1.5m CUREator Grant, which will be used to progress its second generation ocular implant as a treatment for patients with glaucoma, targeting sustained daily dosing for 12 months.
PolyActiva reports promising clinical trial results for its 6-month sustained drug delivery, biodegradable ocular implant in glaucoma patients.
The interim Phase 2a results demonstrate a sustained >20% reduction of IOP after 6 months with a favorable safety profile.
PolyActiva presents positive clinical trial results at the 2022 American Glaucoma Society Annual Meeting – March 2022
PolyActiva successfully completes initial clinical trial with Latanoprost FA SR Ocular Implant delivering glaucoma treatment to patients over a six-month period.
PolyActiva appoints Tracy Valorie, ophthalmic industry expert and former Bausch + Lomb executive, to its Board of Directors.
PolyActiva completes recruitment in key Phase I glaucoma implant safety study. Six-month treatment period demonstrated.